This site is intended for health professionals only

FDA “backs transplant patient drug”

teaser

America’s Food and Drug Administration (FDA) has approved a longer length of therapy for a medication treating adult kidney transplant patients at high risk of cytomegalovirus disease, it has been reported.

Valcyte has been developed by Genentech – a member of the Roche Group.

Cytomegalovirus is a common virus that infects most people at some time, rarely causing problems.

Article continues below this sponsored advert
Advertisement

But it can cause serious infections for patients who have received organ transplants or in immunodeficient patients – for example those with HIV or AIDS.

Genentech said that longer, preventive treatment with Valcyte reduced the incidence of the disease in high-risk patients from 36.8% to 16.8% a year after they received a transplanted kidney.

Copyright Press Association 2010

Genetech






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x